Form 4: Orchestra BioMed Officer Granted 70,000 Stock Options

Orchestra BioMed's Principal Accounting Officer, Joshua Aiello, was granted 70,000 stock options with a $3.82 exercise price, vesting over several years.

Summary

• Joshua Aiello, Principal Accounting Officer of Orchestra BioMed Holdings, Inc. (OBIO), was granted 70,000 stock options.
• The stock options have an exercise price of $3.82 per share.
• The grant date for these options was February 12, 2026.
• The options will vest with 25% on February 12, 2027, and the remaining 75% in equal installments every three months thereafter, starting May 12, 2027.
• Vesting is contingent upon Mr. Aiello's continuous service to the company.
• The expiration date for these stock options is February 12, 2036.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, primarily for executive retention and alignment of interests, which are generally beneficial for corporate governance and long-term shareholder value, without indicating any immediate operational or financial performance changes.

Positives

• The grant of stock options aligns the interests of Principal Accounting Officer Joshua Aiello with those of shareholders, incentivizing long-term performance.
• The vesting schedule promotes executive retention, as the options vest over several years, subject to continuous service.

Future Outlook

The vesting schedule for the stock options extends through May 2027 and beyond, indicating an expectation of continued service from the Principal Accounting Officer and a long-term incentive structure tied to future company performance.

Industry Context

StockSavvy.ai notes that the grant of stock options to key executives is a standard practice across industries, particularly in the biotechnology and healthcare sectors, to attract, retain, and motivate talent by aligning their financial interests with the long-term success and share price performance of the company.

Comparison to Industry Standards

• StockSavvy.ai observes that this option grant is consistent with typical executive compensation packages in the U.S. public markets, which often include a mix of base salary, cash bonuses, and equity incentives like stock options or restricted stock units.
• The vesting schedule, with an initial cliff and subsequent quarterly vesting, is a common structure designed to encourage long-term commitment and performance, similar to practices seen at comparable biotech firms such as Moderna or BioNTech for their senior leadership.

Related Party Transactions

• The grant of 70,000 stock options to Joshua Aiello, the Principal Accounting Officer, constitutes a related party transaction between the company and a key executive.

Stakeholder Impact

• Shareholders: Potential future dilution if options are exercised, but also potential benefit from increased executive alignment and motivation.
• Employees (specifically Joshua Aiello): Significant incentive and potential for future wealth creation tied to company performance.

Next Steps

• The stock options will begin to vest on February 12, 2027, with subsequent vesting occurring quarterly thereafter.
• Joshua Aiello's continuous service is required for the options to vest.

Key Dates

Keywords

Orchestra BioMed Holdings, OBIO, Stock Options, Executive Compensation, Insider Transaction, Form 4, Equity Grant, Vesting Schedule